CUTISS will open CUTISS Innovation, a wholly-owned subsidiary based at Europe’s largest leading technology park Sophia Antipolis, in Q2 2022, following the transfer of technology and recruitment of key professionals. The company has also secured its first grant of EUR 300,000 from the Provence-Alpes-Côte d'Azur region that will be used to set up and launch the research laboratory.
CUTISS is a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering. It is developing the first personalized and automated skin tissue therapy offering life-saving and life-changing medical treatments for patients with severe skin injuries. CUTISS Innovation will support and extend the company’s R&D activities, focusing on the development of innovative break-throughs and products in the field of skin pigmentation restoration, and the automation of personalized regenerative medicine. As part of this, the company will work in close collaboration with dermatology stakeholders, clinics, and specialists, notably with Professor Thierry Passeron, Head of the Dermatology Unit at the Nice University Hospital and Team Leader of the Molecular Medicine Mediterranean Center.
Vincent Ronfard, Chief Innovation Officer at CUTISS AG and Director of CUTISS Innovation, commented: “We are excited to establish our presence in this hotspot for innovation and dermatology which will enable our research team to push the boundaries in regenerative medicine. We are extremely grateful for the support we have received so far, particularly from the regional government who awarded the grant, and from Team Côte d’Azur and Sophia Antipolis Technopole.”
(Press release / SK)
Please login or sign up to comment.
Commenting guidelines